

| | | | | | | | | | | | | | |
|---|----|--|--|--------------------------------------|--|------------------------|--|------|-----------------|-------|----------|----------------------------------|----|
| FORM PTO-1449 (REV. 7-80) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO.: 200.1079CON2 | | SERIAL NO.: 10/056,340 | | | | | | | |
| LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary) | | | | APPLICANT(S): Ronald M. BURCH et al. | | GROUP: 1639 | | | | | | | |
| | | | | FILING DATE: January 25, 2002 | | | | | | | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| *EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | AA | | | | | | | | | | | | |
| | AB | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| | | DOCUMENT NUMBER | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | | | | | | | YES | NO |
| | AC | | | | | | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| | AD | Statement Before the Food and Drug Administration's Arthritis Drugs Advisory Committee on the Nonsteroidal anti-inflammatory Drug Celecoxib. (HRG Publication #1465); December 1, 1998; obtained from http://www.citizen.org/publications/print_release.cfm?ID=6653 on October 28, 2008. | | | | | | | | | | | |
| | AE | NDA 020938 Approval letter and label April 13, 2000; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AF | NDA 20-938 Medical Review, completed August 31, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AG | NDA 20-938 Pharmacology Review(s), completed September 17, 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AH | NDA 20-938 Clinical Pharmacology and Biopharmaceutics Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AI | NDA 20-938 Correspondence, 1998-1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AJ | NDA 20-938 Administrative Documents, 1998; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AK | NDA 20-938 Chemistry Review(s), 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AL | NDA 20-938 Microbiology Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AM | NDA 20-938 Statistical Review(s) 1999; obtained from http://www.accessdata.fda.gov on October 16, 2008 | | | | | | | | | | | |
| | AN | Therapeutics Initiative, February 1995 | | | | | | | | | | | |
| | AO | Therapeutics Initiative, January 1997 | | | | | | | | | | | |
| | AP | Therapeutics Initiative, January/February 2001 | | | | | | | | | | | |
| | AQ | Prescribing Points, volume 8.4, June 1999 | | | | | | | | | | | |
| | AR | | | | | | | | | | | | |
| | AS | | | | | | | | | | | | |
| EXAMINER | | | | | | | | | DATE CONSIDERED | | | | |
| *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |

